亚太药业(002370.SZ)发布上半年业绩，归母净利润1.05亿元，增长1820.97%

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) reported a significant decline in revenue while achieving a substantial increase in net profit, indicating a complex financial performance for the first half of 2025 [1] Financial Performance - The company's operating revenue for the first half of 2025 was 152 million yuan, a year-on-year decrease of 31.48% [1] - Net profit attributable to shareholders reached 105 million yuan, reflecting a remarkable year-on-year increase of 1820.97% [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 48.86 million yuan, which represents an expansion of 524.31% year-on-year [1] - Basic earnings per share stood at 0.14 yuan [1]